Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates
touchPANEL DISCUSSION for touchONCOLOGY
Listen to a panel of leading experts discuss the emerging role of antibody-drug conjugates (ADCs) in the treatment of patients with non-small cell lung cancer (NSCLC), including the mechanistic rationale and role of biomarkers in patient selection, the latest efficacy and safety data, and dose-finding strategies for optimal use in NSCLC.
The experts:
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from AstraZeneca. This activity is provided by touchIME.
For further information please visit: https://touchoncology.com/education/pd-navigating-the-nsclc-treatment-pathway-focus-on-adcs/
Create your
podcast in
minutes
It is Free